Jove
Visualize
Contact Us

Related Experiment Videos

RU 486 beyond the controversy: implications for health care practice

M A Castle1, F M Coeytaux

  • 1Planned Parenthood of New York City.

Journal of the American Medical Women'S Association (1972)
|September 1, 1994
PubMed
Summary

Mifeprex (RU 486) integration into US clinical practice is examined, focusing on maintaining quality care and patient safety. The paper addresses concerns and proposes organizational adaptations for wider access to this medication.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of patient experience on practice: the acceptability of emergency contraceptive pills in inner-city clinics.

Journal of the American Medical Women's Association (1972)·1998
Same author

Abortion education for residents.

Obstetrics and gynecology·1996
Same author

Response to medicine and abortion issue.

Journal of the American Medical Women's Association (1972)·1996
Same author

Knowledge and perceptions of medical abortion among potential users.

Family planning perspectives·1995
Same author

Listening and learning from women about mifepristone: implications for counseling and health education.

Women's health issues : official publication of the Jacobs Institute of Women's Health·1995
Same author

Defining maternal depletion syndrome.

American journal of public health·1993
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Medical Practice
  • Reproductive Health
  • Pharmaceuticals

Background:

  • Mifeprex (RU 486) has faced controversy since its synthesis in the 1980s.
  • Anticipation of US availability necessitates proactive integration strategies.
  • Understanding patient and logistical factors is crucial for safe implementation.

Purpose of the Study:

  • To examine the integration of Mifeprex (RU 486) into US clinical practice.
  • To identify strategies for maintaining quality of care and patient safety.
  • To address potential challenges and facilitate access to reproductive health services.

Main Methods:

  • Review of Mifeprex (RU 486) mechanisms of action and prostaglandin augmentation.
  • Discussion of clinical and logistical issues, including patient follow-up and facility needs.

Related Experiment Videos

  • Analysis of patient acceptance and impact on underserved populations.

    • Main Results:

    • Mifeprex (RU 486) presents unique challenges regarding patient adherence and healthcare infrastructure.
    • Successful integration requires addressing concerns about follow-up visits and backup care.
    • The medication has the potential to improve interpersonal aspects of healthcare and expand access.

    Conclusions:

    • Clinicians must adapt care organization to safely integrate Mifeprex (RU 486).
    • Addressing patient acceptance and logistical hurdles is key to maximizing benefits.
    • Strategic implementation can enhance reproductive healthcare services, particularly for underserved women.